Management of Bradycardia in Elderly Patients on Beta-Blockers

Assessment and Management

• The American Heart Association recommends determining if bradycardia is symptomatic (dizziness, lightheadedness) or asymptomatic in patients on beta-blockers 1
• The American College of Cardiology suggests checking for signs of hypoperfusion (confusion, altered mental status, hypotension) in patients with bradycardia 1
• The European Society of Cardiology recommends evaluating for presence of second or third-degree heart block on ECG in patients on beta-blockers 2
• Review of medication list for other drugs that may cause bradycardia or heart block is recommended by the American Heart Association 1

Dose Adjustment and Monitoring

• The American College of Cardiology recommends reducing the dose of carvedilol if bradycardia is symptomatic, while also evaluating for other potential drug interactions causing bradycardia 1, 2
• The European Heart Journal suggests that in elderly patients, especially those ≥75 years, lower doses of beta-blockers are generally better tolerated 4
• Heart rate monitoring (target >50 BPM if asymptomatic, higher if symptomatic) is recommended by the American Heart Association 1
• Blood pressure monitoring (watch for hypotension) is suggested by the American College of Cardiology 1

Special Considerations

• The European Society of Cardiology notes that elderly patients have decreased baroreceptor response and increased drug sensitivity, which can affect beta-blocker therapy 4
• The American Geriatrics Society recommends considering the possibility that bradycardia may be more pronounced in elderly patients due to age-related changes in drug metabolism 4
• Maintenance doses of beta-blockers should be lower in patients ≥75 years, according to the European Heart Journal 4

Potential Pitfalls and Caveats

• The American College of Cardiology warns that abrupt withdrawal of beta-blockers can lead to clinical deterioration and should be avoided 2
• The European Heart Journal recommends tapering beta-blockers gradually to prevent rebound effects if discontinuation is necessary 3
• The American Heart Association suggests evaluating for underlying cardiac conduction disorders that may be unmasked by beta-blockade 2
• The European Society of Cardiology notes that carvedilol has both beta and alpha-blocking properties, which may contribute to its hemodynamic effects 6